Compare Amphastar Pharmaceuticals Inc (AMPH) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Norwegian Cruise Line Holdings Ltd trades at $19.96 (market cap $9.00B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 10.9× Amphastar Pharmaceuticals Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | NCLH | |
|---|---|---|
Market Cap | $826.08M | $9.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $26.94 |
52-Week Low | $16.87 | $14.79 |
Enterprise Value | $1.22B | $23.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Norwegian Cruise Line Holdings (NCLH) trades at $19.61, down 0.76% on the day, with technical indicators showing a neutral to bearish bias amid recent volatility. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 surpassing expectations of $0.15, while revenue reached $9.83 billion in 2025. Analyst sentiment remains largely positive with a consensus price target of $22.06, though high debt levels and macroeconomic sensitivities present ongoing risks.
NCLH offers potential upside based on earnings momentum and favorable valuation multiples, but investors face headwinds from elevated leverage and industry-specific volatility. The stock's near-term direction hinges on Q2 2026 earnings delivery and sustained travel demand amid fluctuating fuel costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
